Drug Trial Radar · NCT07682129
Long-Term Extension Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon Skipping to Evaluate the Safety and Efficacy of Endosomal Escape Vehicle Phosphorodiamidate Morpholino Oligomer Platform Products (ELEVATE-LTE)
Last checked: Nov 20, 2026Latest source record: Jul 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
80
Planned (sponsor's estimate)
Start
Aug 2026
Primary completion
Mar 2032
Study completion Mar 2032
Sponsor
- Lead sponsor
- Entrada Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jul 2, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 4 years, up to 20 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a study of investigational medicines ENTR-601-44 and ENTR-601-45 designed to evaluate the long-term safety and tolerability of study drugs in participants with Duchenne muscular dystrophy (DMD). The investigational medicines are currently being investigated in multiple ascending dose parent studies. After participants complete their respective parent study, there is a need to understand the effects of long-term administration of ENTR-601-44 and ENTR-601-45. Participants enrolling in this study will begin this long-term extension (LTE) study at the dose level they received upon completion of the parent study with possible dose escalation in the LTE study based on emerging safety and efficacy data from the parent studies. Participants will: * Receive study treatment in the form of multiple intravenous (IV) infusions (slow injections) into a vein over the course of several weeks * Visit the clinic regularly for checkups and tests such as: blood and urine tests, physical examinations, questionnaires, and excersice tests. Participants will have a muscle biopsy at the beginning of their participation and after their last dose to allow researchers to compare whether there have been changes in the muscle as a results of the study drug. Participants are allowed to continue receiving their standard of care therapy for DMD during the study, as long as their health remains stable.
Conditions
- Duchenne Muscular Dystrophy (DMD)
Interventions
ENTR-601-44Drug
ENTR-601-44 intravenous infusion
ENTR-601-45Drug
ENTR-601-45 intravenous infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with Treatment Emergent Adverse Events (TEAEs) according to study protocol (Part A and OL Period)Time frame: From baseline through End of Study (up to 2 years).
Locations
17 sites in 5 countries. Site status is shown where the registry gives one.
University Hospital Gent
Ghent, Belgium
UZ Leuven
Leuven, Belgium
Centre Hospitalier Régional de la Citadelle
Liège, Belgium
IRCCS Ospedale San Raffaele
Milan, Italy
Fondazione Serena Onlus - Centro Clinico NeMO Milano
Milan, Italy
Fondazione Policlinico Universitario A. Gemelli IRCCS - Universita Cattolica del Sacro Cuore
Roma, Italy
Ospedale Pediatrico Bambino Gesu
Rome, Italy
Leids Universitair Medisch Centrum
Leiden, Netherlands
Stichting Radboud Universitair Medisch Centrum
Nijmegen, Netherlands
Hospital Universitario Vall d'Hebron
Barcelona, Spain
Hospital Sant Joan de Deu
Barcelona, Spain
Leeds General Infirmary
Leeds, United Kingdom
Alder Hey Children's NHS Foundation Trust
Liverpool, United Kingdom
Great Ormond Street Hospital for Children
London, United Kingdom
Royal Manchester Children's Hospital
Manchester, United Kingdom
Freeman Hospital
Newcastle upon Tyne, United Kingdom
Oxford University Hospitals NHS Foundation Trust
Oxford, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.